Cardiac Biomarkers Market Size & Growth Forecast 2027–2036, By Segments (Type, End Use, Application), Regional Demand Trends (North America, Asia Pacific, Europe), Key Country Insights (U.S., Japan, South Korea, Germany, France, Italy), and Competitive Landscape
Market Size and Growth Outlook
Cardiac Biomarkers Market size was assessed at USD 23.02 billion in 2026 and is poised to grow at a 10.93% CAGR between 2027 and 2036, crossing USD 64.95 billion by 2036. The industry revenue for 2027 is calculated at USD 25.14 billion.
Get more details on this report
Request Free Sample ReportCardiac Biomarkers Market Intelligence Snapshot
Regional Market Dynamics
- North America held a 45.69% share in 2026, supported by established hospital networks, advanced diagnostic laboratories, and routine use of biomarker testing in acute cardiac care.
- Asia Pacific is forecast to expand at a 16.13% CAGR as healthcare systems strengthen diagnostic capacity, improve hospital infrastructure, and increase adoption of advanced cardiac biomarker testing.
Segment Momentum
- Laboratory Testing remains the leading end-use segment because it supports high testing volumes, standardized workflows, and consistent analytical performance across routine hospital and acute cardiac care settings.
- CK-MB is gaining momentum because clinicians increasingly use it alongside primary biomarkers to provide additional diagnostic insight where multi-marker evaluation supports cardiac injury assessment.
Market Expansion Drivers
- Rising cardiovascular disease burden increasing demand for early and accurate diagnostic biomarker testing.
- Expanding point-of-care cardiac testing improving rapid diagnosis in emergency and outpatient settings.
- Advancements in multi-marker panels and high-sensitivity assays improving precision cardiovascular diagnostics.
Leading Market Participants
- Top companies in the cardiac biomarkers market include Abbott Laboratories (United States), F. Hoffmann-La Roche Ltd. (Switzerland), Siemens Healthineers AG (Germany), Danaher Corporation (United States), QuidelOrtho Corporation (United States), bioMérieux SA (France), Bio-Rad Laboratories, Inc. (United States), Randox Laboratories Ltd. (United Kingdom), Beckman Coulter, Inc. (United States), Thermo Fisher Scientific Inc. (United States).
Global Market Forecast Snapshot
Market Outlook
- 2026 Market Size: USD 23.02 billion
- 2027 Estimated Market Size: USD 25.14 billion.
- Projected Market Size: USD 64.95 billion by 2036
- Growth Forecast: 10.93% CAGR (2027-2036)
Regional and Segment Outlook
- Leading Regional Market: North America
- High-Growth Regional Hub: Asia Pacific
- Core Revenue Segment: Troponin (Type) | Laboratory Testing (End Use) | Acute Coronary Syndrome (Application)
- Emerging Opportunity Segment: CK-MB (Type) | Point of Care Testing (End Use) | Myocardial Infarction (Application)
Market Growth Drivers and Industry Trends
Rising cardiovascular disease burden increasing demand for early and accurate diagnostic biomarker testing
The growing burden of cardiovascular disease is increasing the need for timely and reliable diagnostic assessment, supporting greater use of biomarker-based testing across clinical workflows. Cardiac biomarkers market demand is strengthened as healthcare providers prioritize earlier identification of cardiac injury and more accurate evaluation of patients presenting with suspected cardiovascular conditions, particularly where rapid diagnostic decisions can influence treatment pathways.
Expanding point-of-care cardiac testing improving rapid diagnosis in emergency and outpatient settings
The expansion of point-of-care testing is making cardiac biomarker assessment more accessible at the site of care, reducing reliance on centralized laboratory workflows. In emergency and outpatient environments, cardiac biomarkers market growth is supported by the need for rapid diagnostic information that enables clinicians to evaluate suspected cardiac events efficiently and make treatment decisions closer to the patient.
Advancements in multi-marker panels and high-sensitivity assays improving precision cardiovascular diagnostics
Advances in high-sensitivity assays and multi-marker testing are enabling more refined evaluation of cardiovascular conditions by improving the detection and interpretation of relevant biological signals. Cardiac biomarkers market adoption is benefiting as healthcare providers seek greater diagnostic precision, with broader marker panels supporting more comprehensive patient assessment and high-sensitivity technologies strengthening the ability to identify cardiac abnormalities at earlier stages.
| Growth Driver | Impact on CAGR | Regulatory Influence | Geographic Relevance | Adoption Rate | Impact Timeline |
|---|---|---|---|---|---|
| Rising cardiovascular disease burden increasing demand for early and accurate diagnostic biomarker testing | 2.60% | High | North America, Europe | High | Near Term |
| Expanding point-of-care cardiac testing improving rapid diagnosis in emergency and outpatient settings | 2.30% | High | North America, Asia Pacific | High | Near Term |
| Advancements in multi-marker panels and high-sensitivity assays improving precision cardiovascular diagnostics | 2.00% | High | Europe, North America | High | Mid Term |
Unlock insights tailored to your business with our bespoke market research solutions.
Click to get your customized report now.
Regional Demand Dynamics
North America (Largest Region)
North America dominated the cardiac biomarkers market with a 45.69% share in 2026, supported by advanced diagnostic infrastructure, established cardiovascular care capabilities, and widespread adoption of sophisticated laboratory testing. Strong clinical emphasis on early disease detection and ongoing integration of biomarker-based diagnostics into cardiovascular care are reinforcing regional demand.
Asia Pacific (Fastest-Growing Region)
Asia Pacific is the fastest-growing region, driven by expanding healthcare infrastructure, improving access to advanced diagnostic technologies, and rising demand for cardiovascular disease detection. Growing healthcare investment and broader adoption of modern laboratory testing are creating favorable conditions for increased use of cardiac biomarkers across the region.
| Parameter | North America | Asia Pacific | Europe | Latin America | MEA |
|---|---|---|---|---|---|
| Innovation Hub i Scale Nascent Developing Advanced | |||||
| Cost-Sensitive Region i Scale Low Medium High | |||||
| Regulatory Environment i Scale Restrictive Neutral Supportive | |||||
| Demand Drivers i Scale Weak Moderate Strong | |||||
| Development Stage i Scale Emerging Developing Developed | |||||
| Adoption Rate i Scale Low Medium High | |||||
| New Entrants / Startups i Scale Sparse Moderate Dense | |||||
| Macro Indicators i Scale Weak Stable Strong |
Key Country Insights
Germany 🇩🇪
Laboratory Quality EmphasisGermany focuses on high-quality cardiac biomarker testing supported by established laboratory networks and hospital diagnostics. Clinical stakeholders prioritize standardized testing methods that strengthen diagnostic confidence and workflow efficiency.
France 🇫🇷
Clinical Testing OptimizationFrance advances cardiac biomarker utilization through integrated hospital diagnostics and cardiovascular disease management programs. Laboratories focus on improving testing accuracy and turnaround times to strengthen routine clinical practice.
Italy 🇮🇹
Acute Care DiagnosticsItaly prioritizes cardiac biomarkers within emergency medicine and specialized cardiology services. Healthcare providers emphasize dependable diagnostic testing that enables faster assessment of suspected cardiac events and supports appropriate treatment planning.
Japan 🇯🇵
Early Detection PriorityJapan emphasizes cardiac biomarkers for early cardiovascular disease detection within its aging population. Healthcare institutions continue adopting sensitive diagnostic technologies that support timely intervention and effective patient monitoring.
South Korea 🇰🇷
Hospital Diagnostic InnovationSouth Korea expands cardiac biomarker adoption through advanced hospital laboratories and modern diagnostic infrastructure. Providers seek rapid testing platforms that improve emergency department efficiency and support evidence-based cardiovascular care.
United States 🇺🇸
Precision Diagnostic ExpansionThe U.S. cardiac biomarkers market benefits from broad adoption of advanced diagnostic testing across emergency care and cardiology services. Healthcare providers prioritize rapid and accurate biomarker assessments to support timely clinical decision-making and patient management.
Segment Leadership and Growth Trends
Cardiac Biomarkers Market Share (%), by Type, 2026
Go beyond the chart, access full insights & data tables
Request Free Sample ReportType Segment Analysis: Troponin (Largest Segment) vs CK-MB (Fastest-Growing Segment)
Troponin dominated the cardiac biomarkers market, representing a 37.42% share in 2026, owing to its established importance in the assessment of cardiac injury and acute cardiovascular conditions. Troponin testing is widely incorporated into clinical evaluation pathways because elevated levels can provide valuable evidence of myocardial damage. The growing burden of cardiovascular disease and continued emphasis on timely diagnosis support sustained demand for troponin-based testing. Advances in laboratory and diagnostic technologies that facilitate sensitive biomarker detection further reinforce its role in cardiac assessment.
CK-MB is experiencing the fastest growth as healthcare providers continue to seek complementary biomarkers for evaluating cardiac events and supporting clinical decision-making. Its established association with myocardial injury allows it to remain relevant in diagnostic workflows where clinicians require additional information alongside other cardiac markers. Continued development of cardiovascular diagnostic practices, growing demand for rapid assessment, and the need for effective differentiation of cardiac conditions are supporting renewed utilization of CK-MB testing.
End Use Segment Analysis: Laboratory Testing (Largest Segment) vs Point of Care Testing (Fastest-Growing Segment)
Laboratory testing represented the largest end-use segment in the cardiac biomarkers market in 2026, supported by the established infrastructure and analytical capabilities available in centralized diagnostic laboratories. Laboratory settings enable cardiac biomarker testing to be integrated into comprehensive diagnostic workflows, with standardized procedures and access to advanced analytical systems. Hospitals and diagnostic facilities rely on laboratory testing to support the evaluation of suspected cardiac conditions, while continued emphasis on accurate and reliable biomarker analysis sustains demand within this segment.
Point of care testing is advancing at the fastest rate as healthcare systems place greater emphasis on rapid diagnosis and decentralized clinical decision-making. Point-of-care cardiac biomarker testing can provide results closer to the patient, supporting timely assessment in emergency and other acute-care environments. The growing need to shorten diagnostic workflows, improve treatment responsiveness, and extend testing capabilities beyond centralized laboratories is encouraging broader adoption of point-of-care solutions.
| Segment | Sub-Segment | Largest Segment | Fastest Growing |
|---|---|---|---|
| Type | Troponin, CK-MB, Myoglobin, BNP and NT-proBNP, Others | Troponin | CK-MB |
| End Use | Laboratory Testing, Point of Care Testing | Laboratory Testing | Point of Care Testing |
| Application | Acute Coronary Syndrome, Myocardial Infarction, Congestive Heart Failure, Others | Acute Coronary Syndrome | Myocardial Infarction |
Competitive Landscape and Market Positioning
Leading companies in the cardiac biomarkers market:
1. Abbott Laboratories (United States)
2. F. Hoffmann-La Roche Ltd. (Switzerland)
3. Siemens Healthineers AG (Germany)
4. Danaher Corporation (United States)
5. QuidelOrtho Corporation (United States)
6. bioMérieux SA (France)
7. Bio-Rad Laboratories Inc. (United States)
8. Randox Laboratories Ltd. (United Kingdom)
9. Beckman Coulter Inc. (United States)
10. Thermo Fisher Scientific Inc. (United States)
The cardiac biomarkers market is advancing through improved diagnostic precision and faster disease detection capabilities. Collaborative research initiatives are enhancing biomarker validation and clinical application. Continuous introduction of advanced diagnostic kits is expanding testing capabilities, while technological integration is strengthening laboratory efficiency in the cardiac biomarkers market.
| Company | Market Share | Company Revenue | Revenue CAGR (%) | Product Portfolio | Geographic Presence | Innovation / R&D Focus | Strategic Developments |
|---|---|---|---|---|---|---|---|
| Abbott Laboratories (United States) | |||||||
| F. Hoffmann-La Roche Ltd. (Switzerland) | |||||||
| Siemens Healthineers AG (Germany) | |||||||
| Danaher Corporation (United States) | |||||||
| QuidelOrtho Corporation (United States) | |||||||
| bioMérieux SA (France) | |||||||
| Bio-Rad Laboratories Inc. (United States) | |||||||
| Randox Laboratories Ltd. (United Kingdom) | |||||||
| Beckman Coulter Inc. (United States) | |||||||
| Thermo Fisher Scientific Inc. (United States). |
Industry Development/News
| Company Name | Date | Key Development |
|---|---|---|
| QuidelOrtho Corp. | Nov-25 | QuidelOrtho received FDA 510(k) clearance for its VITROS hs Troponin I Reagent Pack. This high-sensitivity assay is designed for the quantitative measurement of cardiac troponin I in human plasma to aid in the diagnosis of myocardial infarction. The rollout enables laboratories using VITROS systems to integrate guideline-aligned, high-sensitivity testing into existing workflows to improve diagnostic speed and patient outcomes. |
| Adaptyx | Oct-25 | Adaptyx secured USD 14 million in seed funding to advance its wearable platform for continuous multi-analyte molecular monitoring. This development reflects a strategic investment in next-generation diagnostic hardware capable of real-time physiological and biomarker tracking, aiming to transition cardiac monitoring from episodic clinical testing to continuous, wearable-enabled remote patient observation. |
| Roche | Sep-25 | Roche announced positive results from its TSIX Study Program for the Elecsys Troponin T hs Gen 6 assay. The sixth-generation high-sensitivity test demonstrated high precision in identifying acute myocardial infarction and excluding non-AMI cases. Following its recent CE Mark approval, this assay supports more efficient triage and clinical decision-making in emergency departments by enabling rapid, reliable patient assessment. |
| OMRON Healthcare | Jul-25 | OMRON Healthcare collaborated with Tricog to launch KeeboHealth, an AI-enabled remote cardiac care platform in India. The platform integrates connected monitoring technologies to track cardiac health indicators, aiming to improve early detection of cardiovascular risks. This initiative underscores a strategic push toward data-driven, continuous remote patient monitoring to enhance long-term management and reduce the incidence of cardiac events. |
| Heart Foundation | May-25 | The Heart Foundation introduced a home heart health kit as part of its “Heart First” initiative. The solution integrates a wearable ECG patch, saliva biosensor, and wireless ultrasound to facilitate comprehensive at-home cardiac monitoring. By enabling multi-modal biomarker and physiological signal tracking, the project aims to increase the accessibility of early detection for heart-related conditions outside of traditional clinical settings. |
| bioMérieux | Jan-25 | bioMérieux entered an agreement to acquire SpinChip Diagnostics ASA, a developer of a rapid point-of-care immunoassay platform. This acquisition strengthens bioMérieux’s position in the point-of-care market by integrating SpinChip’s benchtop analyzer, which delivers high-sensitivity cardiac troponin I and NT-proBNP results from whole blood within 10 minutes, facilitating faster emergency care and reduced hospital turnaround times. |
| Siemens Healthineers | Oct-24 | The Atellica IM High-Sensitivity Troponin I (TnIH) test received U.S. FDA clearance for a new prognostic claim, allowing it to predict major adverse cardiac events and death up to one year post-presentation. This expansion of clinical utility beyond acute diagnosis enables clinicians to perform better risk stratification and long-term management for patients presenting with signs of acute coronary syndrome. |
Customize Your Report
Explore examples of how this report can be tailored to different research needs, including custom segments, additional topics or chapters, and related reports. Click a section of the wheel or its numbered marker to explore the available options.
Cardiac Biomarkers Market — Custom Segments
| Segment | Sub-Segment |
|---|---|
| Testing Technology | Immunoassay-Based Testing, Molecular Testing, Chromatographic Testing, Biosensor-Based Testing |
| Sample Type | Blood, Plasma, Serum, Urine, Other Biological Samples |
| Care Setting | Emergency Departments, Intensive Care Units, Cardiology Departments, Outpatient & Ambulatory Care, Diagnostic Laboratories |
Cardiac Biomarkers Market — Custom TOC
| Custom Chapter | Custom Details |
|---|---|
| Cardiovascular Disease Screening Opportunities |
|
| Biomarker Pipeline and Innovation Assessment |
|
| Personalized Cardiology Market Opportunities |
|
Need a different cut of the data?
Request Custom ResearchWhat is the current size of the cardiac biomarkers market?
How much is the cardiac biomarkers industry expected to grow by 2036?
How is rising cardiovascular disease burden impacting demand for cardiac biomarker testing?
How is point-of-care testing reshaping cardiac biomarker diagnostics in clinical workflows?
Why does Laboratory Testing lead the cardiac biomarkers market?
Why is CK-MB the fastest-growing biomarker segment in the cardiac biomarkers market?
What factors make North America the leading cardiac biomarkers market?
Why is Asia Pacific experiencing the fastest growth in the cardiac biomarkers market?
Who are the leading players in the cardiac biomarkers landscape?
Our Clients
"The team took the time to understand our specific business needs and delivered a report that was well aligned with our objectives. Their expertise and understanding of the industry were clearly reflected in the quality and relevance of the insights provided."
Siemens Healthcare
"Our experience in acquiring the research report has been excellent. The depth of analysis, and actionable insights provided have been extremely valuable in supporting our ongoing R&D efforts."
GC Biopharma
"The report offered a comprehensive view of the market trends. The in-depth segmentation and analysis of emerging opportunities gave us a better understanding of the market."
Medtronic
Our Research Team & Methodology
Every Fundamental Business Insights report is built by a dedicated vertical research team, validated through a structured primary-and-secondary methodology, and reviewed for accuracy before it reaches you.
Research Team Overview
Prepared by the Healthcare & Medical Devices Research Team
Delivery
Published
Demand
Available
Support
Trust & Compliance
Research Domains
10 coverage areasResearch Intelligence
| Source | Reference |
|---|---|
| World Health Organization (WHO) | www.who.int |
| U.S. Food & Drug Administration (FDA) | www.fda.gov |
| European Medicines Agency (EMA) | www.ema.europa.eu |
| Centers for Disease Control and Prevention (CDC) | www.cdc.gov |
| National Institutes of Health (NIH) | www.nih.gov |
| National Center for Biotechnology Information (NCBI) | www.ncbi.nlm.nih.gov |
| PubMed | pubmed.ncbi.nlm.nih.gov |
| ClinicalTrials.gov | clinicaltrials.gov |
| International Organization for Standardization (ISO) | www.iso.org |
| ASTM International | www.astm.org |
| Advanced Medical Technology Association (AdvaMed) | www.advamed.org |
| Medical Device Innovation Consortium (MDIC) | mdic.org |
| Biotechnology Innovation Organization (BIO) | www.bio.org |
| International Federation of Pharmaceutical Manufacturers & Associations (IFPMA) | www.ifpma.org |
| U.S. Pharmacopeia (USP) | www.usp.org |
| European Directorate for the Quality of Medicines & HealthCare (EDQM) | www.edqm.eu |
| World Organisation for Animal Health (WOAH) | www.woah.org |
| American Hospital Association (AHA) | www.aha.org |
| OECD Health | www.oecd.org/health |
| World Bank Data | data.worldbank.org |
Research Workflow & Quality Assurance
Data Collection
Verified information gathered through primary and secondary research.
Data Triangulation
Cross-validation using multiple independent data sources.
Forecast Modelling
Market estimates developed using historical trends and analytical models.
Analyst Validation
Findings reviewed by domain experts for accuracy and consistency.
Editorial & Quality Review
Final editorial, quality, and compliance checks before publication.
Final Publication
Released after successful completion of the internal review process.
Report Coverage
📊 Market Assessment
- Market Size & Forecast
- Market Segmentation
- Regional Analysis
- Growth Drivers & Challenges
- Market Dynamics
🏢 Competitive Intelligence
- Competitive Landscape
- Company Profiles
- Competitive Benchmarking
- Mergers & Acquisitions
- Market Share Analysis or Key Company Strategies
🔍 Strategic Analysis
- Value Chain Analysis
- Porter's Five Forces
- PESTLE Analysis
- Pricing Trends
- Supply-Demand Analysis
🚀 Future Outlook
- Technology Landscape
- Regulatory Landscape
- Investment & Funding Landscape
- Emerging Opportunities
- Future Market Outlook
Have a question about this report or need a custom scope?
Request Customization